Kentucky 2022 Regular Session

Kentucky House Bill HB42

Introduced
1/4/22  

Caption

AN ACT relating to the establishment of emergency insulin programs and declaring an emergency.

Impact

Should this legislation pass, there are significant implications for Kentucky's healthcare landscape, particularly for diabetic patients. It removes financial barriers by guaranteeing access to insulin for those in urgent need and creates a structured process for pharmacies to dispense these substances efficiently. By mandating manufacturers to develop procedures for claims and reporting to the Kentucky Board of Pharmacy, it secures accountability while also focusing on the necessity of insulin access in emergency situations.

Summary

House Bill 42 introduces two key programs in Kentucky: the Urgent-Need Insulin Program and the Continuing Access to Insulin Program. These initiatives aim to ensure that residents in urgent need can access insulin affordably, particularly those without coverage under existing health assistance programs. The bill defines parameters for eligibility, including residency and financial criteria, and establishes a framework for how pharmacists and manufacturers will interact to provide this essential medication.

Sentiment

The overall sentiment surrounding HB42 appears mostly positive from those advocating for diabetic patients' rights and healthcare access. Supporters believe the bill addresses a critical issue affecting thousands by converting what is often a lifesaving medication into a more accessible resource. However, there may be contention surrounding the restrictions placed on eligibility, specifically related to existing health insurance coverage, which may leave some individuals without access.

Contention

One notable point of contention revolves around eligibility restrictions for the Urgent-Need Insulin Program, particularly those individuals already enrolled in certain health plans. Critics argue this could lead to inequities in access, leaving out many who might still struggle to afford insulin. The bill’s enforcement mechanisms also involve financial penalties for manufacturers who fail to comply with the regulations, which could spark debate on the appropriateness and effectiveness of such measures in ensuring access to healthcare resources.

Companion Bills

No companion bills found.

Similar Bills

KY HB141

AN ACT relating to the establishment of emergency insulin programs and declaring an emergency.

KY SB126

AN ACT relating to the establishment of emergency insulin programs and declaring an emergency.

KY HB806

AN ACT relating to pharmaceutical manufacturers.

KY SB27

AN ACT relating to pharmaceutical manufacturers.

KY HB274

AN ACT relating to the practice of pharmacy.

KY SB134

AN ACT relating to prescription drugs.

KY SB170

AN ACT relating to pharmacy.

KY SB68

AN ACT relating to prescription drugs.